Results 251 to 260 of about 146,874 (392)

Survival After Brain Metastases From Breast Cancer in the Trastuzumab Era [PDF]

, 2005
David G. Kirsch, Carlos J. Ledezma, Christina S. Mathews, Atul K. Bhan, Marek Ancukiewicz, Fred H. Hochberg, Jay S. Loeffler   +6 more
openalex   +1 more source

Tumor microenvironment delineates differential responders to trastuzumab emtansine in HER2-positive metastatic breast cancer patients previously treated with pyrotinib: an exploratory biomarker analysis of a phase II study (NJMU-BC02). [PDF]

Signal Transduct Target Ther
Pan H, Wang J, Sun Y, Li F, Sun C, Liu M, Xu H, Tao J, Mao X, Wang C, Wang S, Li W, Ding Q, Zhou W.   +13 more
europepmc   +1 more source

Cardiovascular Disease Meets Cancer: Exploring the Epidemiology in China and Homotherapy Targeting Intersectional Mechanisms

Advanced Science, Volume 12, Issue 37, October 6, 2025.
Cardiovascular disease (CVD) and cancer are leading causes of death worldwide, with overlapping risk factors and pathophysiological mechanisms. This review explores shared pathways, including metabolic dysregulation, chronic inflammation, and gut microbiome alterations, highlighting dual‐benefit strategies such as lifestyle modifications and repurposed
Shihan Xiang, Yujie Shan, Shihong Xu, Jing Wang, Meng Luo, Jiaojiao Zhou, Qishan Chen   +6 more
wiley   +1 more source

Continuation of Trastuzumab Beyond Disease Progression [PDF]

, 2005
Filippo Montemurro, R. Faggiuolo, Stefania Redana, Michela Donadio, Monica Minischetti, Antonio Durando, Guido Vietti-Ramus, R. Buosi, Massimo Aglietta   +8 more
openalex   +1 more source

Characterizing the Healthcare Utilization and Costs of Hereditary Hemorrhagic Telangiectasia

American Journal of Hematology, Volume 100, Issue 10, Page 1722-1735, October 2025.
ABSTRACT Hereditary hemorrhagic telangiectasia (HHT) is the second‐most common inherited bleeding disorder worldwide, afflicting one in 4000–5000 people, and is the most morbid inherited bleeding disorder of women. HHT causes recurrent severe epistaxis, chronic gastrointestinal bleeding, heavy menstrual bleeding, and arteriovenous malformations in the ...
Hanny Al‐Samkari, Tracy J. Mayne, Misty Troutt, Hemant Patle, Marianne Clancy, Eric Duhaime   +5 more
wiley   +1 more source

AGO Recommendations for Diagnosis and Treatment of Patients with Early and Metastatic Breast Cancer: Update 2012 [PDF]

, 2011
Harbeck, Nadia, Scharl, Anton, Thomssen, Christoph   +2 more
core   +2 more sources

Adjuvant trastuzumab for HER2-positive breast cancer [PDF]

, 2005
James Spicer, Mark Harries, Peter Ellis
openalex   +1 more source

Complete Response With Alpelisib and Trastuzumab in a Patient With Estrogen Receptor-/Progesterone Receptor-Negative, Human Epidermal Growth Factor Receptor 2-Positive Refractory Metastatic Breast Cancer. [PDF]

JCO Precis Oncol
Gibson S, Shah F, Parajuli R.
europepmc   +1 more source

A Surface Plasmon Resonance‐Based Integrated Assay for Quantification and Glycosylation Characterization of Monoclonal Antibodies in Crude Heterogeneous Samples

Biotechnology and Bioengineering, Volume 122, Issue 10, Page 2724-2738, October 2025.
ABSTRACT The rise in cancer, autoimmune, inflammatory, and infectious diseases in recent decades has led to a surge in the development of monoclonal antibodies (mAbs) therapies, now the most widely used family of biologics. To meet the growing global demand, biopharmaceutical industries are intensifying their production processes.
Ilona Metayer, Catherine Forest‐Nault, Julie Guimond, Simon Joubert, Olivier Henry, Yves Durocher, Gregory De Crescenzo, Jimmy Gaudreault   +7 more
wiley   +1 more source

Neoadjuvant Therapy With Trastuzumab, Paclitaxel and Epirubicin for HER-2–Positive Operable Breast Cancer [PDF]

, 2005
Manmeet S. Ahluwalia, Hamed Daw
openalex   +1 more source